Head-To-Head Review: BeyondAirInc . (XAIR) & The Competition
BeyondAirInc . (NASDAQ: XAIR) is one of 127 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare BeyondAirInc . to similar businesses based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, dividends, valuation and risk.
Valuation and Earnings
This table compares BeyondAirInc . and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BeyondAirInc .||$7.72 million||-$6.56 million||-5.83|
|BeyondAirInc . Competitors||$1.43 billion||$145.31 million||-12.03|
This table compares BeyondAirInc . and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|BeyondAirInc . Competitors||-674.05%||-624.80%||-22.23%|
This is a summary of recent recommendations and price targets for BeyondAirInc . and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|BeyondAirInc . Competitors||950||3182||5391||284||2.51|
As a group, “Surgical & medical instruments” companies have a potential upside of 20.91%. Given BeyondAirInc .’s peers higher possible upside, analysts clearly believe BeyondAirInc . has less favorable growth aspects than its peers.
Institutional and Insider Ownership
5.4% of BeyondAirInc . shares are owned by institutional investors. Comparatively, 51.4% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Risk and Volatility
BeyondAirInc . has a beta of -0.25, meaning that its share price is 125% less volatile than the S&P 500. Comparatively, BeyondAirInc .’s peers have a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.
BeyondAirInc . peers beat BeyondAirInc . on 7 of the 10 factors compared.
BeyondAirInc . Company Profile
Beyond Air, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory tract infections and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. The company is based in Garden City, New York.
Receive News & Ratings for BeyondAirInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondAirInc . and related companies with MarketBeat.com's FREE daily email newsletter.